

Supporting Information for:

**Enantioselective construction of substituted hydantoins via
chiral phosphoric acid catalyzed annulation/Heyns
rearrangement of aryl-substituted ureas with glyoxals**

Yong Wang,^a Jingyuan Li,^b Yanyan Li,^a Chao Pi,^a Yangjie Wu,^a and Xiuling Cui^{*a}

^a Henan Key Laboratory of Chemical Biology and Organic Chemistry, Key Laboratory of Applied Chemistry of Henan Universities, Green Catalysis Center, and College of Chemistry, Zhengzhou University, Zhengzhou 450052, China

^b School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China

*E-mail: cuixl@zzu.edu.cn


Table of Contents:

I. General Information	S2
II. Optimization of the Reaction Conditions	S2
III. General Procedure and Characterization of Products 4	S3
IV. Control Experiments	S10
V. Gram-scale Synthesis and Further Chemical Transformations	S12
VI. References	S13
VII. Copies of NMR Spectra	S14
VIII. Copies of HPLC Spectra	S40

I. General Information

Unless otherwise noted, substrates, catalysts and solvents were obtained from commercial suppliers and used without further purification. The urea **1e**, **1i-1k** were prepared according to the literatures.¹ Products **3** were visualized by UV-light at 254 nm. Flash chromatography was conducted on silica gel (200–300 mesh). The ¹H NMR, ¹³C NMR and ¹⁹F NMR spectra were obtained using a Bruker AVANCE III spectrometer at 400, 100 and 376 MHz, respectively. Chemical shifts are reported in units of parts per million (ppm) downfield from tetramethylsilane (TMS), and all coupling constants are reported in hertz. Peak multiplicity is indicated as follows: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, m = multiplet, and broad = b. Enantiomeric excesses values were determined with HPLC on Chiral Daicel Chiralpak AS-H and AD-H (mobile phase: hexane/ⁱPrOH). Optical rotation were measured on a Anton Paar MCP 4100 polarimeter and reported as follows: [α]_D 20 (c = g/100 mL, solvent). Melting points were uncorrected. All high-resolution mass spectra were obtained on an TOF LC/MS equipped with an ESI source.

II. Optimization of the Reaction Conditions




entry	CPA	1/3	solvent	yield (%) ^b	ee (%) ^c
1	4a	1a/3aa	toluene	61	14
2	4a	1b/3ba	toluene	23	92
3	4a	1c/3ca	toluene	50	0
4	4a	1d/3da	toluene	quant.	28
5	4b	1b/3ba	toluene	80	78
6	4c	1b/3ba	toluene	87	89
7	4d	1b/3ba	toluene	45	89
8	4e	1b/3ba	toluene	41	-68
9	4f	1b/3ba	toluene	quant.	-38
10	4h	1b/3ba	toluene	27	33
11	4i	1b/3ba	toluene	98	78
12	4j	1b/3ba	toluene	48	86
13	4k	1b/3ba	toluene	80	78


14	4l	1b/3ba	toluene	quant.	-33
15	4m	1b/3ba	toluene	18	92
16	4n	1b/3ba	toluene	93	48
17	4o	1b/3ba	toluene	quant.	45
18 ^d	4a	1b/3ba	PhCl	quant.	91
19 ^d	4a	1b/3ba	<i>o</i> -xylene	97	91
20 ^d	4a	1b/3ba	<i>m</i> -xylene	85	85
21 ^d	4a	1b/3ba	<i>p</i> -xylene	89	75
22 ^d	4a	1b/3ba	benzene	73	95
23 ^d	4a	1b/3ba	CCl ₄	quant.	94
24 ^d	4a	1b/3ba	mesitylene	51	93
25 ^d	4a	1b/3ba	PhCF ₃	quant.	90
26 ^e	4a	1b/3ba	benzene	quant.	95
27 ^e	4g	1b/3ba	benzene	quant.	96

^aReaction conditions: **1** (0.05 mmol), **2a** (0.075 mmol), CPA (10 mol %), solvent (2 mL), rt, 16 h, air. ^bIsolated yields, quant. = quantitative yield. ^cDetermined by chiral HPLC. ^d90 °C. ^e**1b** (0.12 mmol), **2a** (0.1 mmol), CPA (10 mol %), solvent (2 mL), 90 °C, 16 h, air.

III. General Procedure and Characterization of Products **3**




The urea **1** (0.12 mmol), glyoxal hydrate **2** (0.1 mmol) and CPA (10 mol %) was dissolved in benzene (2 mL). The reaction mixture was stirred at 90 °C for 16 h. The crude product was separated by flash column chromatography on silica gel to afford target products **3**.




(*S*)-1,3,5-triphenylimidazolidine-2,4-dione (**3ba**).²

Product **3ba** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 35.4 mg, 96% ee. M.p.: 124-125 °C. ¹H NMR (CDCl₃) δ : 7.53 (d, *J* = 7.9 Hz, 2H), 7.50-7.43 (m, 4H), 7.43-7.33 (m, 6H), 7.30 (t, *J* = 8.4 Hz, 2H), 7.11 (t, *J* = 7.4 Hz, 1H), 5.61 (s, 1H); ¹³C NMR (CDCl₃) δ : 168.9, 153.6, 136.3, 132.9, 131.4, 129.3, 129.2, 129.1, 129.1, 128.4, 126.8, 126.5, 126.3, 125.0, 120.6, 64.1; $[\alpha]_D^{20} = +25.9$ (*c* 0.4, DCM). Chiral HPLC: Chiralpak AD-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 270 nm; t_R = 36.0 min (minor), 77.4 min (major).




(S)-5-phenyl-1,3-di-*p*-tolylimidazolidine-2,4-dione (3ea).

Product **3ea** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 36.7 mg, 95% ee. M.p.: 166-168 °C. ¹H NMR (CDCl₃) δ: 7.43-7.29 (m, 9H), 7.29-7.23 (m, 2H), 7.09 (d, *J* = 8.3 Hz, 2H), 5.56 (s, 1H), 2.37 (s, 3H), 2.26 (s, 3H); ¹³C NMR (CDCl₃) δ: 169.2, 153.8, 138.5, 134.8, 133.8, 133.1, 129.8, 129.7, 129.3, 129.2, 128.8, 126.9, 126.2, 120.8, 64.3, 21.2, 20.8; HRMS (ESI) *m/z* calcd for C₂₃H₂₁N₂O₂⁺ (M+H)⁺ 357.1598, found 357.1597. [α]_D²⁰ = +25.2 (*c* 0.4, DCM). Chiral HPLC: Chiralpak AD-H, hexane:ⁱPrOH = 60:40, 0.5 mL/min, 270 nm; t_R = 42.8 min (minor), 69.2 min (major).




(S)-1,3-bis(4-methoxyphenyl)-5-phenylimidazolidine-2,4-dione (3fa).

Product **3fa** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 42.9 mg, 90% ee. M.p.: 68-70 °C. ¹H NMR (CDCl₃) δ: 7.41-7.28 (m, 9H), 7.00-6.93 (m, 2H), 6.85-6.79 (m, 2H), 5.52 (s, 1H), 3.81 (s, 3H), 3.73 (s, 3H); ¹³C NMR (CDCl₃) δ: 169.4, 159.4, 157.0, 154.1, 133.2, 129.3, 129.2, 127.7, 127.1, 124.2, 123.0, 114.4, 114.4, 64.7, 55.5, 55.4; HRMS (ESI) *m/z* calcd for C₂₃H₂₁N₂O₄⁺ (M+H)⁺ 389.1496, found 389.1496. [α]_D²⁰ = +32.3 (*c* 0.4, DCM). Chiral HPLC: Chiralpak AS-H, hexane:ⁱPrOH = 60:40, 0.5 mL/min, 270 nm; t_R = 37.0 min (minor), 123.2 min (major).




(S)-1,3-bis(4-fluorophenyl)-5-phenylimidazolidine-2,4-dione (3ga).

Product **3ga** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 37.1 mg, 93% ee. M.p.: 131-133 °C. ¹H NMR (CDCl₃) δ: 7.50-7.41 (m, 4H), 7.41-7.30 (m, 5H), 7.20-7.10 (m, 2H), 7.04-6.91 (m, 2H), 5.56 (s, 1H); ¹³C NMR (CDCl₃) δ: 168.8, 163.4, 161.0, (d, *J* = 19.0 Hz), 158.7, 153.6, 132.5, 132.2 (d, *J* = 2.9 Hz), 129.5, 128.2 (d, *J* = 8.8 Hz), 127.3 (d, *J* = 3.1 Hz), 126.9, 122.8 (d, *J* = 8.1 Hz), 116.3 (d, *J* = 11.5 Hz), 116.0 (d, *J* = 11.2 Hz), 64.5; ¹⁹F NMR (CDCl₃): -112.2, -116.4. HRMS (ESI) *m/z* calcd for C₂₁H₁₅F₂N₂O₂⁺ (M+H)⁺ 365.1096, found 365.1098. [α]_D²⁰ = +32.0 (*c* 0.4, DCM). Chiral HPLC: Chiralpak AS-H, hexane:ⁱPrOH = 60:40, 0.5 mL/min, 270 nm; t_R = 21.7 min (minor), 30.4 min (major).




(S)-1,3-bis(4-chlorophenyl)-5-phenylimidazolidine-2,4-dione (3ha).

Product **3ha** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 42.2 mg, 95% ee. M.p.: 158-161 °C. ¹H NMR (CDCl₃) δ: 7.49-7.32 (m, 11H), 7.29-7.21 (m, 2H), 5.56 (s, 1H); ¹³C NMR (CDCl₃) δ: 168.4, 153.2, 134.8, 134.4, 132.3, 130.5, 129.8, 129.6, 129.4, 129.3, 127.5, 126.8, 121.8, 64.1; HRMS (ESI) m/z calcd for C₂₁H₁₄Cl₂N₂O₂Na⁺ (M+Na)⁺ 419.0325, found 419.0324. [α]_D²⁰ = +16.8 (c 0.4, DCM). Chiral HPLC: Chiralpak AS-H, hexane:PrOH = 60:40, 0.5 mL/min, 270 nm; tR = 24.7 min (minor), 45.5 min (major).




(S)-1,3-bis(4-bromophenyl)-5-phenylimidazolidine-2,4-dione (3ia).

Product **3ia** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 52.8 mg, 98% ee. M.p.: 207-208 °C. ¹H NMR (CDCl₃) δ: 7.62-7.56 (m, 2H), 7.44-7.31 (m, 11H), 5.55 (s, 1H); ¹³C NMR (CDCl₃) δ: 168.3, 153.1, 135.3, 132.4, 132.3, 132.2, 130.3, 129.6, 127.7, 126.7, 122.4, 122.0, 118.2, 64.0; HRMS (ESI) m/z calcd for C₂₁H₁₄Br₂N₂O₂Na⁺ (M+Na)⁺ 506.9314, found 506.9311. [α]_D²⁰ = +22.1 (c 0.5, DCM). Chiral HPLC: Chiralpak AS-H, hexane:PrOH = 60:40, 0.5 mL/min, 270 nm; tR = 23.4 min (minor), 49.6 min (major).



(S)-1,3-bis(2-methoxyphenyl)-5-phenylimidazolidine-2,4-dione (3ja).


Product **3ja** was obtained by flash chromatography (PE:EA = 2:1) in 93% yield as white solid. 35.9 mg, 68% ee. M.p.: 75-76 °C. ¹H NMR (CDCl₃) δ: 7.43-7.26 (m, 7H), 7.23-7.15 (m, 2H), 7.10-6.98 (m, 2H), 6.92-6.79 (m, 2H), 5.68 (s, 1H), 3.88 (s, 3H), 3.85 (s, 3H); ¹³C NMR (CDCl₃) δ: 170.9, 155.2, 154.9, 154.9, 134.2, 130.8, 130.1, 130.0, 129.1, 129.0, 128.9, 128.2, 123.8, 121.0, 120.8, 120.6, 112.2, 111.9, 66.2, 56.0, 55.7; HRMS (ESI) m/z calcd for C₂₃H₂₀N₂O₄Na⁺ (M+Na)⁺ 411.1315, found 411.1313. [α]_D²⁰ = +5.5 (c 0.4, DCM). Chiral HPLC: Chiralpak AS-H, hexane:PrOH = 60:40, 0.5 mL/min, 270 nm; tR = 13.9 min (minor), 28.2 min (major).



(S)-3-benzyl-1,5-diphenylimidazolidine-2,4-dione (3ka).³


Product **3ka** was obtained by flash chromatography (PE:EA = 10:1) in quantitative yield as white

solid. 76 % ee. M.p.: 183-185 °C. ¹H NMR (CDCl₃) δ: 7.48-7.40 (m, 4H), 7.36-7.21 (m, 10H), 7.06 (t, *J* = 7.4 Hz, 1H), 5.44 (s, 1H), 4.76 (q, *J* = 17.5 Hz, 2H); ¹³C NMR (CDCl₃) δ: 169.7, 154.4, 136.4, 135.8, 132.8, 129.3, 129.2, 129.1, 128.8, 128.1, 126.7, 124.7, 120.2, 64.2, 42.9; HRMS (ESI) *m/z* calcd for C₂₂H₁₉N₂O₂⁺ (M+H)⁺ 343.1441, found 343.1442. [α]_D²⁰ = +46.6 (*c* 0.4, DCM). Chiral HPLC: Chiralpak AD-H, hexane:PrOH = 60:40, 0.5 mL/min, 254 nm; t_R = 19.2 min (minor), 26.2 min (major).




(S)-1,3-diphenyl-5-(*p*-tolyl)imidazolidine-2,4-dione (3bb).

Product **3bb** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as colorless oil. 34.9 mg, 83% ee. ¹H NMR (CDCl₃) δ: 7.56-7.50 (m, 2H), 7.50-7.42 (m, 4H), 7.41-7.34 (m, 1H), 7.33-7.25 (m, 4H), 7.18 (d, *J* = 8.0 Hz, 2H), 7.10 (t, *J* = 7.4 Hz, 1H), 5.57 (s, 1H), 2.31 (s, 3H); ¹³C NMR (CDCl₃) δ: 169.2, 153.7, 139.3, 136.4, 131.5, 130.1, 129.9, 129.2, 129.1, 128.5, 126.8, 126.4, 125.0, 120.7, 64.0, 29.7, 21.2; HRMS (ESI) *m/z* calcd for C₂₂H₁₉N₂O₂⁺ (M+H)⁺ 343.1441, found 343.1442. [α]_D²⁰ = +29.8 (*c* 0.3, DCM). Chiral HPLC: Chiralpak AS-H, hexane:PrOH = 60:40, 0.5 mL/min, 254 nm; t_R = 20.6 min (minor), 31.5 min (major).




(S)-5-(4-methoxyphenyl)-1,3-diphenylimidazolidine-2,4-dione (3bc).

Product **3bc** was obtained by flash chromatography (PE:EA = 5:1) in 97% yield as white solid. 34.6 mg, 87% ee. M.p.: 56-58 °C. ¹H NMR (CDCl₃) δ: 7.55-7.50 (m, 2H), 7.50-7.43 (m, 4H), 7.42-7.36 (m, 1H), 7.36-7.28 (m, 4H), 7.12 (t, *J* = 7.4 Hz, 1H), 6.90 (d, *J* = 8.8 Hz, 2H), 5.57 (s, 1H), 3.77 (s, 3H); ¹³C NMR (CDCl₃) δ: 169.3, 160.3, 153.6, 136.4, 131.5, 129.2, 129.1, 128.5, 128.1, 126.4, 125.0, 124.8, 120.8, 114.9, 63.7, 55.3; HRMS (ESI) *m/z* calcd for C₂₂H₁₉N₂O₃⁺ (M+H)⁺ 359.1390, found 359.1390. [α]_D²⁰ = +17.3 (*c* 0.3, DCM). Chiral HPLC: Chiralpak AS-H, hexane:PrOH = 60:40, 0.5 mL/min, 270 nm; t_R = 34.0 min (minor), 41.3 min (major).




(S)-5-(4-fluorophenyl)-1,3-diphenylimidazolidine-2,4-dione (3bd).

Product **3bd** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 35.3 mg. 95% ee. M.p.: 55-57 °C. ¹H NMR (CDCl₃) δ: 7.54-7.42 (m, 6H), 7.50-7.43 (m, 4H), 7.42-7.35 (m, 3H), 7.35-7.27 (m, 2H), 7.13 (tt, *J* = 7.4, 0.9 Hz, 1H), 7.10-7.02 (m, 2H), 5.60 (s, 1H); ¹³C NMR (CDCl₃) δ: 168.8, 163.1 (d, *J* = 248.8 Hz), 153.5, 136.2, 131.3, 129.2 (d, *J* = 9.9 Hz), 129.0, 128.8, 128.7, 128.6, 128.6, 126.3, 125.2, 120.7, 116.5 (d, *J* = 22.0 Hz), 63.4; ¹⁹F NMR (CDCl₃): -111.8. HRMS (ESI) *m/z* calcd for C₂₁H₁₆FN₂O₂⁺ (M+H)⁺ 347.1190, found 347.1190. [α]_D²⁰ = +32 (*c* 0.1, DCM). Chiral HPLC: Chiralpak AD-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 270 nm; t_R = 33.5 min (minor), 84.4 min (major).




(S)-5-(4-chlorophenyl)-1,3-diphenylimidazolidine-2,4-dione (3be).

Product **3be** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 40.5 mg. 86% ee. M.p.: 149-150 °C. ¹H NMR (CDCl₃) δ: 7.53-7.37 (m, 7H), 7.36-7.27 (m, 6H), 7.13 (t, *J* = 7.4 Hz, 1H), 5.59 (s, 1H); ¹³C NMR (CDCl₃) δ: 168.6, 153.5, 136.1, 135.3, 131.4, 131.3, 129.7, 129.3, 129.2, 128.6, 128.2, 126.3, 125.2, 120.6, 63.4. HRMS (ESI) *m/z* calcd for C₂₁H₁₆ClN₂O₂⁺ (M+H)⁺ 363.0895, found 363.0895. [α]_D²⁰ = +34.3 (*c* 0.3, DCM). Chiral HPLC: Chiralpak AS-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 270 nm; t_R = 25.7 min (minor), 61.7 min (major).




(S)-5-(4-bromophenyl)-1,3-diphenylimidazolidine-2,4-dione (3bf).

Product **3bf** was obtained by flash chromatography (PE:EA = 5:1) in 88% yield as white solid. 35.6 mg. 75% ee. M.p.: 166-168 °C. ¹H NMR (CDCl₃) δ: 7.54-7.36 (m, 9H), 7.35-7.25 (m, 4H), 7.13 (t, *J* = 7.4 Hz, 1H), 5.57 (s, 1H); ¹³C NMR (CDCl₃) δ: 168.4, 153.5, 136.1, 132.6, 131.9, 131.3, 129.3, 129.2, 128.8, 128.6, 128.5, 126.3, 125.3, 123.5, 120.6, 63.5. HRMS (ESI) *m/z* calcd for C₂₁H₁₅BrN₂O₂Na⁺ (M+Na)⁺ 429.0209, found 429.0209. [α]_D²⁰ = +27.2 (*c* 0.4, DCM). Chiral HPLC: Chiralpak AS-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 254 nm; t_R = 23.5 min (minor), 35.8 min (major).




(S)-1,3-diphenyl-5-(4-(trifluoromethyl)phenyl)imidazolidine-2,4-dione (3bg).

Product **3bg** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as colorless oil. 40.1 mg. 60% ee. $^1\text{H NMR}$ (CDCl_3) δ : 7.55-7.49 (m, 2H), 7.49-7.27 (m, 8H), 7.21 (d, $J = 7.8$ Hz, 1H), 7.17-7.09 (m, 2H), 7.084 (td, $J = 8.4, 2.2$ Hz, 1H), 5.60 (s, 1H); $^{13}\text{C NMR}$ (CDCl_3) δ : 168.4, 163.2 (d, $J = 248.2$ Hz), 153.5, 136.2, 135.3 (d, $J = 7.3$ Hz), 131.3, 131.1 (d, $J = 8.2$ Hz), 129.3 (d, $J = 12.8$ Hz), 128.6, 126.3, 125.2, 122.6 (d, $J = 3.0$ Hz), 120.6, 116.4 (d, $J = 21.2$ Hz), 114.1 (d, $J = 23.0$ Hz), 63.5 (d, $J = 1.6$ Hz); $^{19}\text{F NMR}$ (CDCl_3): -110.9. HRMS (ESI) m/z calcd for $\text{C}_{22}\text{H}_{16}\text{F}_3\text{N}_2\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 397.1158, found 397.1155. $[\alpha]_D^{20} = +22.6$ (c 0.4, DCM). Chiral HPLC: Chiralpak AS-H, hexane: i PrOH = 60:40, 0.5 mL/min, 270 nm; $t_R = 16.8$ min (minor), 24.7 min (major).



(S)-5-(3-fluorophenyl)-1,3-diphenylimidazolidine-2,4-dione (3bh).


Product **3bh** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as colorless oil. 35.7 mg. 91% ee. $^1\text{H NMR}$ (CDCl_3) δ : 7.55-7.49 (m, 2H), 7.49-7.27 (m, 8H), 7.21 (d, $J = 7.8$ Hz, 1H), 7.17-7.09 (m, 2H), 7.04 (td, $J = 8.4, 2.2$ Hz, 1H), 5.60 (s, 1H); $^{13}\text{C NMR}$ (CDCl_3) δ : 168.4, 163.2 (d, $J = 248.2$ Hz), 153.5, 136.2, 135.3 (d, $J = 7.3$ Hz), 131.3, 131.1 (d, $J = 8.2$ Hz), 129.3, 129.2, 128.6, 126.3, 125.2, 122.6 (d, $J = 3.0$ Hz), 120.6, 116.4 (d, $J = 21.1$ Hz), 114.1 (d, $J = 23.0$ Hz), 63.5 (d, $J = 1.5$ Hz); $^{19}\text{F NMR}$ (CDCl_3): -110.9. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{16}\text{FN}_2\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 347.1190, found 347.1187. $[\alpha]_D^{20} = +25.7$ (c 0.4, DCM). Chiral HPLC: Chiralpak AS-H, hexane: i PrOH = 60:40, 0.5 mL/min, 270 nm; $t_R = 22.3$ min (minor), 48.9 min (major).



(S)-5-(3-chlorophenyl)-1,3-diphenylimidazolidine-2,4-dione (3bi).


Product **3bi** was obtained by flash chromatography (PE:EA = 5:1) in 95% yield as white solid. 34.3 mg. 85% ee. M.p.: 135-136 °C. $^1\text{H NMR}$ (CDCl_3) δ : 7.56-7.36 (m, 8H), 7.36-7.26 (m, 5H), 7.17-7.11 (m, 1H), 5.58 (s, 1H); $^{13}\text{C NMR}$ (CDCl_3) δ : 168.3, 153.5, 136.1, 135.4, 134.9, 131.3, 130.7, 129.6, 129.4, 129.2, 128.6, 127.2, 126.3, 125.3, 125.0, 120.6, 63.5. HRMS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{16}\text{ClN}_2\text{O}_2^+$ ($\text{M}+\text{H}$) $^+$ 363.0895, found 363.0894. $[\alpha]_D^{20} = +27.5$ (c 0.4, DCM). Chiral HPLC:

Chiralpak AS-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 270 nm; tR = 26.8 min (minor), 42.1 min (major).




(S)-5-(3-bromophenyl)-1,3-diphenylimidazolidine-2,4-dione (3bj).

Product **3bj** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 41.0 mg. 81% ee. M.p.: 138-139 °C. ¹H NMR (CDCl₃) δ: 7.58 (t, *J* = 1.7 Hz, 1H), 7.54-7.36 (m, 8H), 7.36-7.28 (m, 3H), 7.25 (t, *J* = 7.8 Hz, 1H), 7.17-7.10 (m, 1H), 5.57 (s, 1H); ¹³C NMR (CDCl₃) δ: 168.3, 153.5, 136.1, 135.1, 132.6, 131.3, 130.9, 130.0, 129.4, 129.2, 128.6, 126.3, 125.4, 125.3, 123.5, 120.6, 63.4. HRMS (ESI) *m/z* calcd for C₂₁H₁₆BrN₂O₂⁺ (M+H)⁺ 407.0390, found 407.0387. [α]_D²⁰ = +25.7 (*c* 0.4, DCM). Chiral HPLC: Chiralpak AS-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 254 nm; tR = 26.6 min (minor), 56.3 min (major).



(S)-5-(2-fluorophenyl)-1,3-diphenylimidazolidine-2,4-dione (3bk).


Product **3bk** was obtained by flash chromatography (PE:EA = 5:1) in quantitative yield as white solid. 35.2 mg. 80% ee. M.p.: 74-74 °C. ¹H NMR (CDCl₃) δ: 7.53-7.44 (m, 6H), 7.44-7.37 (m, 1H), 7.35-7.26 (m, 4H), 7.15-7.06 (m, 3H), 5.86 (s, 1H); ¹³C NMR (CDCl₃) δ: 168.7, 163.2 (d, *J* = 249.5 Hz), 153.6, 135.8, 131.5, 131.4 (d, *J* = 8.4 Hz), 129.6 (d, *J* = 2.8 Hz), 129.2, 129.2, 128.6, 126.5, 125.6, 124.9 (d, *J* = 3.6 Hz), 121.6, 116.5 (d, *J* = 20.8 Hz), 59.8 (d, *J* = 1.5 Hz); ¹⁹F NMR (CDCl₃): -117.9. [α]_D²⁰ = +20.0 (*c* 0.1, DCM). Chiral HPLC: Chiralpak AD-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 254 nm; tR = 38.4 min (minor), 89.6 min (major).



(S)-5-(naphthalen-2-yl)-1,3-diphenylimidazolidine-2,4-dione (3bl).


Product **3bl** was obtained by flash chromatography (PE:EA = 5:1) in 98% yield as white solid. 37.2 mg. 71% ee. M.p.: 158-160 °C. ¹H NMR (CDCl₃) δ: 7.89 (s, 1H), 7.86 (t, *J* = 8.5 Hz, 1H), 7.83-7.77 (m, 2H), 7.57 (d, *J* = 8.4 Hz, 1H), 7.52-7.41 (m, 7H), 7.41-7.33 (m, 1H), 7.30-7.21 (m, 2H), 7.07 (t, *J* = 7.3 Hz, 1H), 5.75 (s, 1H); ¹³C NMR (CDCl₃) δ: 169.0, 153.7, 136.4, 133.6, 133.3, 131.5, 130.4, 129.6, 129.2, 129.2, 128.5, 128.1, 127.9, 127.1, 126.9, 126.8, 126.4, 125.1, 123.4, 120.7, 64.4. HRMS (ESI) *m/z* calcd for C₂₅H₁₈N₂O₂Na⁺ (M+Na)⁺ 401.1260, found 401.1258. [α]_D²⁰ = +8.8 (*c*

0.4, DCM). Chiral HPLC: Chiralpak AS-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 270 nm; tR = 28.1 min (minor), 50.1 min (major).



(S)-5-(naphthalen-1-yl)-1,3-diphenylimidazolidine-2,4-dione (3bm).


Product **3bm** was obtained by flash chromatography (PE:EA = 5:1) in 86% yield as white solid. 32.5 mg. 60% ee. M.p.: 170-171 °C. ¹H NMR (CDCl₃) δ: 8.36 (br, s, 1H), 7.90 (d, *J* = 8.1 Hz, 1H), 7.83 (d, *J* = 8.2 Hz, 1H), 7.70-7.61 (m, 1H), 7.56 (t, *J* = 7.5 Hz, 1H), 7.54-7.42 (m, 7H), 7.41-7.35 (m, 2H), 7.22 (t, *J* = 8.4 Hz, 2H), 7.05 (t, *J* = 7.4 Hz, 1H), 6.51 (br, s, 1H), 5.75 (s, 1H); ¹³C NMR (CDCl₃) δ: 168.8, 153.8, 136.4, 134.5, 131.5, 131.3, 129.9, 129.2, 129.1, 128.5, 127.2, 126.4, 126.4, 125.4, 124.9, 123.4, 120.0, 59.9. HRMS (ESI) *m/z* calcd for C₂₅H₁₉N₂O₂⁺ (M+H)⁺ 379.1441, found 379.1443. [α]_D²⁰ = +37.8 (*c* 0.3, DCM). Chiral HPLC: Chiralpak AS-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 270 nm; tR = 22.2 min (minor), 33.6 min (major).





(S)-5-cyclohexyl-1,3-diphenylimidazolidine-2,4-dione (3bn).

Product **3bn** was obtained by flash chromatography (PE:EA = 5:1) in 98% yield as colorless oil. 32.8 mg. 92% ee. ¹H NMR (CDCl₃) δ: 7.51-7.34 (m, 9H), 7.29-7.24 (m, 1H), 4.58 (d, *J* = 2.8 Hz, 1H), 2.03-1.92 (m, 1H), 1.84-1.59 (m, 6H), 1.28-0.96 (m, 4H); ¹³C NMR (CDCl₃) δ: 170.5, 153.7, 135.7, 132.0, 131.5, 129.4, 129.1, 128.4, 126.4, 125.9, 122.9, 64.5, 39.0, 27.9, 26.8, 26.2, 25.9. [α]_D²⁰ = +6.7 (*c* 0.1, DCM). Chiral HPLC: Chiralpak AD-H, hexane:*i*PrOH = 60:40, 0.5 mL/min, 254 nm; tR = 26.1 min (major), 35.9 min (minor).


IV. Control experiments




The 1-deuterated phenylglyoxal monohydrate (**d-2a**) was synthesized according to reference.⁴ The urea **1b** (1.2 mmol), **d-2a** (0.1 mmol) and **4g** (10 mol %) was dissolved in benzene (2 mL). The reaction mixture was stirred at 90 °C for 16 h. The product was separated by flash column chromatography (PE:EA = 5:1) on silica gel to afford compound **d-3ba** (35.1 mg, <5%D) in quant yield.




The urea **1b** (1.2 mmol), **2a** (0.1 mmol) and **4g** (10 mol %) was dissolved in benzene (2 mL). The D₂O (4.0 equiv) was added into the mixture. The reaction mixture was stirred at 90 °C for 16 h. The product was separated by flash column chromatography (PE:EA = 5:1) on silica gel to afford compound **d-3ba** (33.4 mg, 71%D) in quant yield.




V. Gram-scale Synthesis and Further Chemical Transformations



The *N,N'*-diphenylurea **1b** (1.2 mmol), **2a** (1.0 mmol) and **4g** (8 mol %) was dissolved in benzene (20 mL). The reaction mixture was refluxed for 16 h. Then solvent was removed in vacuo and the crude product was separated by flash column chromatography on silica gel (PE:EA = 5:1) to afford products **3ba** in quantitative yield with 94% ee.



A solution of **3ba** (0.1 mmol) in THF (0.5 mL) was treated with borane-dimethyl sulfide complex (2 M in THF, 2 equiv) at 0 °C under N₂. The resulting mixture was heated at 60 °C for 6 h and then cooled to 0 °C. The reaction was then quenched with MeOH (0.5 mL) at 0 °C. The solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (PE:EA = 5:1) to afford white solid (24.6 mg) in 78% yield. (*S*)-1,3,4-triphenylimidazolidin-2-one (**4**): white solid, m.p.: 150-152 °C, 94% ee; ¹H NMR (CDCl₃) δ: 7.58 (d, *J* = 8.4 Hz, 2H), 7.43 (d, *J* = 8.2 Hz, 2H), 7.40-7.31 (m, 6H), 7.30-7.19 (m, 3H), 7.08 (t, *J* = 7.3 Hz, 1H), 7.01 (t, *J* = 7.3 Hz, 1H), 5.32 (dd, *J* = 9.2, 5.9 Hz, 1H), 4.33 (t, *J* = 9.0 Hz, 1H), 3.72 (dd, *J* = 9.0, 5.9 Hz, 1H); ¹³C NMR (CDCl₃) δ: 155.5, 140.0, 139.8, 138.7, 129.2, 128.9, 128.7, 128.4, 126.2, 123.7, 123.2, 120.8, 118.2, 57.3, 51.6. HRMS (ESI) *m/z* calcd for C₂₁H₁₉N₂O⁺ (M+H)⁺ 315.1492, found 315.1493. [α]_D²⁰ = -30.5 (*c* 0.2, DCM). Chiral HPLC: Chiralpak AS-H, hexane:PrOH = 80:20, 1.0 mL/min, 254 nm; t_R = 12.5 min (major), 14.3 min (minor).





A solution of **3fa** (0.1 mmol) in THF (0.5 mL) was treated with borane-dimethyl sulfide complex (2 M in THF, 2 equiv) at 0 °C under N₂. The resulting mixture was heated at 60 °C for 6 h and then cooled to 0 °C. The reaction was then quenched with MeOH (0.5 mL) at 0 °C. The solvent was removed under reduced pressure, and the crude product was purified by silica gel column


chromatography (PE:EA = 3:1) to afford white solid. To a solution of the white solid in MeCN (1.5 mL), was added a solution of CAN in water (1.5 mL) slowly in 30 min at 0 °C. Then the solution was extracted with EA, and dried with Na₂SO₄. Then solvent was removed in vacuo and the crude product was separated by flash column chromatography on silica gel (DCM:MeOH = 95:5) to afford products **6** in 63% yield with 81% ee. **(S)-4-phenylimidazolidin-2-one (6)**:⁵ yellow solid, m.p.: 126-128 °C, 81% ee; ¹H NMR (CDCl₃) δ: 7.42-7.29 (m, 5H), 5.09 (br, s, 1H), 4.93 (br, s, 1H), 4.88 (t, *J* = 8.2 Hz, 1H), 3.87 (t, *J* = 8.8 Hz, 1H), 3.35 (t, *J* = 8.1 Hz, 1H); ¹³C NMR (CDCl₃) δ: 141.3, 128.9, 128.3, 126.1, 56.7, 49.6. [α]_D²⁰ = +19.3 (*c* 0.1, DCM). Chiral HPLC: Chiralpak IB-3, hexane:PrOH = 80:20, 1.0 mL/min, 210 nm; tR = 9.0 min (major), 9.8 min (minor).

VI. References


- (1) Wang, M.; Han, J.; Si, X.; Hu, Y.; Zhu, J.; Sun, X., Effective approach to ureas through organocatalyzed one-pot process. *Tetrahedron Lett.* **2018**, *59*, 1614-1618.
- (2) Han, G. H.; Kim, S. Y.; Lee, H. R.; Lee, J. S.; Park, Y. S., A Convenient One-Pot Synthesis of Both Enantiomers of 1,3,5-Trisubstituted Hydantoins. *Synlett* **2020**, *31*, 171-174.
- (3) Xu, Z.-G.; Ding, Y.; Meng, J.-P.; Tang, D.-Y.; Li, Y.; Lei, J.; Xu, C.; Chen, Z.-Z., Facile Construction of Hydantoin Scaffolds via a Post-Ugi Cascade Reaction. *Synlett* **2018**, *29*, 2199-2202.
- (4) Marchand, N. J.; Grée, D. M.; Martelli, J. T.; Grée, R. L.; Toupet, L. J., Synthesis and Reactivity of Cross-Conjugated Polyenones with a Planar Chirality. *J. Org. Chem.* **1996**, *61*, 5063-5072.
- (5) Zhou, Z.; Tan, Y.; Yamahira, T.; Ivlev, S.; Xie, X.; Riedel, R.; Hemming, M.; Kimura, M.; Meggers, E., Enantioselective Ring-Closing C–H Amination of Urea Derivatives. *Chem* **2020**, *6*, 2024-2034.

VII. Copies of NMR Spectra








¹H NMR (400 MHz, CDCl₃) of 3ea




¹³C NMR (100 MHz, CDCl₃) of 3ea








¹H NMR (400 MHz, CDCl₃) of **3ga**




¹³C NMR (100 MHz, CDCl₃) of **3ga**










^{13}C NMR (100 MHz, CDCl_3) of **3ha**




^1H NMR (400 MHz, CDCl_3) of **3ia**




^1H NMR (400 MHz, CDCl_3) of **3ja**







^{13}C NMR (100 MHz, CDCl_3) of **3ka**





^1H NMR (400 MHz, CDCl_3) of **3bb**




^{13}C NMR (100 MHz, CDCl_3) of **3bb**




^1H NMR (400 MHz, CDCl_3) of **3bc**







¹³C NMR (100 MHz, CDCl₃) of **3bd**




¹⁹F NMR (376 MHz, CDCl₃) of **3bd**




¹H NMR (400 MHz, CDCl₃) of **3be**




¹³C NMR (100 MHz, CDCl₃) of **3be**




¹H NMR (400 MHz, CDCl₃) of **3bf**



¹³C NMR (100 MHz, CDCl₃) of **3bf**





¹H NMR (400 MHz, CDCl₃) of **3bg**






¹³C NMR (100 MHz, CDCl₃) of **3bg**


--110.85



¹⁹F NMR (376 MHz, CDCl₃) of **3bg**




¹H NMR (400 MHz, CDCl₃) of **3bh**




¹³C NMR (100 MHz, CDCl₃) of **3bh**


--110.85




¹⁹F NMR (376 MHz, CDCl₃) of **3bh**




¹H NMR (400 MHz, CDCl₃) of **3bi**




¹³C NMR (100 MHz, CDCl₃) of **3bi**




¹H NMR (400 MHz, CDCl₃) of **3bj**





¹³C NMR (100 MHz, CDCl₃) of **3bj**







¹H NMR (400 MHz, CDCl₃) of 3bk







¹³C NMR (100 MHz, CDCl₃) of 3bk


















VIII. Copies of HPLC Spectra

HPLC spectra of 3ba





HPLC spectra of 3ea








HPLC spectra of 3fa




HPLC spectra of 3ga





HPLC spectra of 3ha








HPLC spectra of **3ia**




HPLC spectra of 3ja





HPLC spectra of 3ka








HPLC spectra of 3bb




HPLC spectra of 3bc




HPLC spectra of 3bd






No.	Retention Time	PeakArea	Peak Height	PeakArea(%)	Peak Width	Peak Type
1	33.47	1002349	22185	2.63%	2.245 BB	
2	84.41	37072879	385801	97.37%	6.369 BB	
Total		38,075,228	407,986	100.00%		

HPLC spectra of 3be





No.	Retention Time	PeakArea	Peak Height	PeakArea(%)	Peak Width	Peak Type
1	25.77	1223979	18944	50.65%	2.898 BB	
2	62.86	1192334	6896	49.35%	8.053 BB	
Total		2,416,313	25,840	100.00%		





No.	Retention Time	PeakArea	Peak Height	PeakArea(%)	Peak Width	Peak Type
1	25.74	565716	9016	7.44%	2.89 BB	
2	61.70	7040405	39649	92.56%	11.684 BB	
Total		7,606,121	48,665	100.00%		

HPLC spectra of 3bf





HPLC spectra of 3bg








HPLC spectra of 3bh




HPLC spectra of 3bi





HPLC spectra of 3bj








HPLC spectra of 3bl




HPLC spectra of 3bm





HPLC spectra of 3bn





HPLC spectra of 4



HPLC spectra of 6

